Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sobi
Biotech
Sobi pens $580M deal for Innate’s cancer drug before ph. 3 push
Sobi has handed the French biotech $75 million upfront for the rights to market the anti-KIR3DL2 antibody for an aggressive skin cancer.
James Waldron
Aug 10, 2026 7:13am
After 5-month wait, BioNTech reveals Sobi CEO will take top job
Aug 3, 2026 7:35am
Fierce Pharma
FDA snubs Sobi’s gout drug over manufacturing issues
Jun 29, 2026 11:04am
Sobi pays $950M upfront to snap up gout specialist Arthrosi
Dec 15, 2025 8:15am
Selecta, Sobi rout gout in phase 3 trials to take on Horizon
Mar 21, 2023 7:40am
New federal biotech commission taps 12 members—Chutes & Ladders
Feb 3, 2023 10:20am
Fierce Pharma
Fierce Pharma
Fierce Pharma
Fierce Pharma
